



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/661,398	09/12/2003	H. Robert Horvitz	01997/548003	7921
21559 7590 02/07/2008				
CLARK & ELBING LLP				
101 FEDERAL STREET				
BOSTON, MA 02110				
			EXAMINER	
			HIBBERT, CATHERINE S	
			ART UNIT	PAPER NUMBER
			1636	
			NOTIFICATION DATE	DELIVERY MODE
			02/07/2008	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com

## Office Action Summary

**Application No.**

10/661,398

**Applicant(s)**

HORVITZ ET AL.

**Examiner**

Catherine S. Hibbert

**Art Unit**

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 07 November 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-3 and 22-34 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3 and 22-34 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>11/7/2007</u> .   | 6) <input type="checkbox"/> Other: _____                          |

### DETAILED ACTION

Applicants' Amendment to the Claims filed 1 November 2007 has been received and entered. Applicants' IDS filed 1 November 2007 is acknowledged. Applicants' submittal of Rule 132 Affidavit, filed 1 November 2007, is acknowledged. Claims 4-21 are cancelled. Claims 1-3 and 22-34 are pending and under examination.

### *Priority*

Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosures of the prior-filed applications, Application Nos. 60/437,821 and 60/410,160 fail to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. While the disclosure of the instant application provides support for the genes *lin(n4256)* and *lin-65*, the Provisional Applications 60/437,821 and 60/410,160 do not provide any

support for the *lin(n4256)* and *lin-65* genes as there is no mention of either of these genes in the Provisional Applications.

Therefore, claims 23-30 do not receive the Priority dates of the provisional applications.

The disclosures of the prior-filed applications, Application No. 60/410,160 fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. The Provisional Application 60/410,160 does not provide support for the *lin-15A* and *lin-38* genes.

Therefore, claims 22 and 32 do not receive the Priority dates of the Provisional Application No. 60/410,160.

### ***Response to Arguments***

The rejection of claims 1-3 under 35 U.S.C. § 112, second paragraph, for omitting an essential step, has been withdrawn based on Applicants' Amendment to the Claims, filed 1 November 2007. The rejection of cancelled claim 4 is moot.

The rejection of claims 1-3 under 35 U.S.C. § 112, second paragraph, as being indefinite, has been withdrawn based on Applicants' Amendment to the Claims, filed 1 November 2007. The rejection of cancelled claim 4 is moot.

The rejection of claims 1-3 under 35 U.S.C. § 112, first paragraph, as lacking written description, has been withdrawn based on Applicants' Amendment to the Claims, filed 1 November 2007. The rejection of cancelled claim 4 is moot.

The rejection of claims 1, 2 and 4 under 35 U.S.C. 103(a) as being unpatentable over Duyk *et al.* and further in light of Unhavaithaya *et al.*, has been withdrawn based on Applicants' Amendment to the Claims, filed 1 November 2007. The rejection of cancelled claim 4 is moot.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3 stand rejected and new claims 22-34 are rejected under 35 U.S.C. 112, first paragraph, for reasons of record as stated in the office action mailed 30 April 2007 and for reasons below, because the specification, while being enabling for: a method for identifying a candidate compound that may have potential as a compound that treats a neoplasia, comprising: (a) contacting a *C. elegans* vulval precursor cell comprising a "loss of function" mutation in a Class B synMuv gene and a second "loss of function" mutation in a "Class A synthetic multivulval gene", with a candidate compound, and (b) detecting cell proliferation in the contacted cells compared to control cells, does not reasonably provide enablement for *any cell type* or for *any cell* in a nematode or for *any* isolated mammalian cell. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to

Art Unit: 1636

use the invention commensurate in scope with these claims. The rejection of cancelled claim 4 is moot.

Applicant's arguments filed 1 November 2007 have been fully considered but are respectfully found not persuasive.

Applicants Amendment to the claims have rendered moot several of the reasons for the enablement rejection. However, with respect to the basis for the enablement rejection regarding any cell type, Applicants submit that

given (1) the Examples in the specification and (2) the high degree of structural and functional homology between members of the synthetic multivulval signaling pathway and members of the ras-signaling and Rb-signaling pathways; one skilled in the art of molecular biology would recognize that the method of amended claim 1 and new claims 23, 27, and 31, could predictably be carried out in other cells (for example, additional nematode cell types and mammalian cells).

Applicant's further traverse that "the specification teaches the use of precursor vulval tissue to perform the method of amended claim 1 and new claims 23, 27, and 31" and that, in addition to the teachings of the specification, Applicants submit that

at the time of filing, the high degree of structural and functional homology between the members of the synthetic multivulval signaling pathway to members of the ras-signaling and Rb-signaling pathways was recognized in the field of molecular biology (see, Exhibit 1, Santos and Nebreda, FASEB J. 3:2151-6163, 1989). Santos and Nebreda state (page 2152, left column, second paragraph): "Ras genes appear to be ubiquitous in eukaryotic cells, and yeasts are the lowest organisms found to possess functional ras genes. The remarkable degree of conservation between species as far apart in evolution as yeast and human strongly suggests that ras gene products play a fundamental role in key cellular processes".

In addition, Applicants argue that "the specification further states (page 1, lines 19-28): Retinoblastoma (Rb) family proteins are mammalian tumor suppressors that regulate cell proliferation. This pathway is conserved among a variety of species, including the

nematode, *Caenorhabditis elegans*. LIN-35 Rb, which is the nematode *C. elegans* counterpart of mammalian Rb, is required for normal vulval development in *C. elegans*".

Therefore, Applicants submit that "given the teaching of the specification and the high degree of structural and functional conservation between members of the synthetic multivulval signaling family and members of the ras-signaling and Rb-signaling families, one skilled in the art of molecular biology would recognize that the method of amended claim 1, and new claims 23, 27, and 31, could be performed in a number of cells, including different nematode cell types and mammals cell types".

Applicant's arguments have been fully considered but are respectfully found not persuasive because the amended claims are directed to a method for identifying a candidate compound for treating a neoplasia, said method comprising: (a) contacting a cell comprising a first "loss of function" mutation in a Class B synMuv gene (*mep-1*, *lin(n3628)*, *lin(n4256)*, and *lin-65*) and a second "loss of function" mutation in a Class A synthetic multivulval gene, with a candidate compound; and (b) detecting cell proliferation in the contacted cells compared to control cells. Further limitations are drawn to cells in a nematode (claims 2, 25, 29 and 33) or in an isolated mammalian cell (claims 3, 26, 30 and 34), or to where the Class A synthetic multivulval gene is *lin-15A* or *lin-38* (claims 22, 24, 28 and 32).

Although Applicant's arguments are well taken that Applicant's invention "could be performed in a number of cells, including different nematode cell types and mammals cell types", Applicant's claims are drawn to *any* and *all* types of cells.

In making a determination as to whether an application has met the requirements for enablement under 35 U.S.C. 112 ¶ 1, the courts have put forth a series of factors. See, In re Wands, 8 USPQ2d 1400, at 1404 (CAFC 1988); and Ex Parte Forman, 230 U.S.P.Q. 546 (BPAI 1986). These factors include, but are not limited to: (a) the nature of the invention; (b) the breadth of the claims; (c) the state of the prior art; (d) the amount of direction provided by the inventor; (e) the existence of working examples; (f) the relative skill of those in the art; (g) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue"; and (h) the level of predictability in the art (MPEP 2164.01 (a)). The following factors are relevant in the instant case:

*Nature of the invention:* The nature of Applicant's invention involves determination of potential anti-neoplastic activity by a process involving contacting a mutant cell with a candidate compound and detecting cell proliferation levels in the contacted cells compared to control cells. While the nature of this experiment is technologically feasible within a certain limited scope, the results of performing this assay would not necessarily identify a compound having anti-neoplastic activity and the scope of the claims extends well beyond the scope enabled by the application.

*Breadth of the claims:* Claims are broadly drawn to any type of cell (claims 1, 22-24, 27-28 and 31-32), any type of cell in a nematode (claims 2, 25, 29 and 33) or any type of an isolated mammalian cell (claims 3, 26, 30 and 34). However, the model for the synMuv Class A and Class B mutants is performed using precursor vulval tissue in the nematode *C. elegans* (see especially specification). Even the breadth of the more



limiting claims which read on *any* cell in a nematode or *any type* of an isolated mammalian cell, would still be too broad to ensure the same outcome which is obtained using synMuv mutants in the precursor vulval tissue of *C. elegans*.

*State of the Prior Art and Predictability:* The state of the prior art teaches that the SynMuv phenotype is revealed when mutations are present in genes from both classes A and B. Several class B genes have been identified as components of the Rb transcriptional regulatory-complex and "this finding raises the possibility of cross talk between cell-cycle/transcriptional controllers and known regulators of vulval development including members of the RTK/Ras/map kinase pathway. (Fay and Han), "The Synthetic Multivulval Genes of *C. elegans*: Functional Redundancy, Ras-Antagonism, and Cell Fate Determination", in *Genesis*: 26:279-284 (2000). Fay and Han further point out that "multiple mechanisms could be operating in the generation of the SynMuv phenotype. This possibility seems even more likely given that two distinct classes of mutants are required for the expression of the phenotype. The basic observation that class A and B genes are genetically redundant does not mean that both classes carry out identical biological functions. Malfunctions in two distinct pathways could converge to produce the observed defect. For example, the combination of cell-cycle and transcriptional defects could interfere with cell fusion, if both timing and gene expression are critical to this process. Clearly more work will be necessary to sort out these possibilities and provide a more precise picture of how these processes relate to one another." (p. 283, ¶ 4).

Furthermore, the state of the prior art teaches that the use of isolated mammalian cells are not predictable models of cancer. For example, Zips *et al.* ["In Vitro and In Vivo Evaluation of new Anticancer Agents" In Vivo. 2005 Jan-Feb;19(1):1-7] recites:

"It is obvious that cells in culture represent an artificial and simplified system. Unlike the situation *in vitro*, a tumor is a 3-dimensional complex consisting of interacting malignant and non-malignant cells. Vascularisation, perfusion and, thereby drug access to the tumor cells are not evenly distributed and this fact 'consists' an important source of heterogeneity in tumor response to drugs that does not exist *in vitro*. Therefore, prediction of drug effects in cancer patients based solely on *in vitro* data is not reliable and further evaluation in animal tumor systems is essential." (p.3 col.2)

*Direction provided by the inventor and Existence of working examples:* For the instant invention, the applicant does not provide direction or evidence of working examples to establish whether the invention is enabled for *all cell types*, all cells in a nematode, or all types of isolated mammalian cells. Therefore, the skilled artisan seeking to practice the invention according to its full scope would not be able to predict which embodiments within the broad scope of the claims could be used as claimed.

*Unpredictability and Undue Experimentation:* Because of the reasons stated above, the unpredictability of the outcome of the neoplasia assay would require undue experimentation with various cell types to determine whether the assay would be able to identify candidate compounds for treating neoplasia.

Therefore, claims 1-3 stand rejected and new claims 22-34 are rejected under 35 U.S.C. 112, first paragraph, as lacking an enabling disclosure, for reasons of record and for reasons above.

#### ***New Grounds of Rejection***

The following new grounds of rejection were necessitated by Applicant's Amendments to the Claims filed 7 November 2007.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-3 and 22-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, 23, 27 and 31 are unclear because it is unclear whether the requirement for at least 95% sequence identity to the respective sequences of SEQ ID NO:s 24, 26, 28 and 2, is for a sequence which *includes* the "loss of function" mutation, or alternatively, whether the claims are directed to a "loss of function" mutation in addition to the requirement for a 95% sequence identity to the SEQ ID NO:s, which would then represent a sequence which is less than 95% sequence identity to the respective sequences of SEQ ID NO:s 24, 26, 28 and 2. Therefore, the metes and bounds of Applicants' invention can not be determined.

Claims 2-3, 22, 24-26, 28-30 and 32-34 are indefinite insofar as they depend from claims 1, 23, 27 and 31.

***Conclusion***

No claims allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine S. Hibbert, Ph.D., whose telephone number is 571-270-3053. The examiner can normally be reached on Monday-Friday, 7:30 AM-5:00 PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D., can be reached on 571-272-0739. The fax phone

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patent Examiner: Catherine S. Hibbert

  
DAVID GUZO  
PRIMARY EXAMINER